Acción BDRL BLONDER TONGUE LABORATORIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Blonder Tongue Laboratories, Inc.

Acciones

BDRL

US0936981085

Mercado cerrado - OTC Markets
Otros sitios de cotización
 21:51:30 15/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,12 USD +5,18 % Gráfico intradía de Blonder Tongue Laboratories, Inc. +9,09 % +47,24 %
2023 Blonder Tongue anuncia la incorporación de una función de conmutación por error de IP al sistema de entrega de vídeo NXG CI
2023 Blonder Tongue Laboratories, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2022 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Blonder Tongue Announces IP Failover Feature Added to NXG Video Delivery System
BLONDER TONGUE LABORATORIES INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Tranche Update on Blonder Tongue Laboratories, Inc.'s Equity Buyback Plan announced on February 13, 2007.
Tranche Update on Blonder Tongue Laboratories, Inc.'s Equity Buyback Plan announced on July 24, 2002.
Blonder Tongue Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Blonder Tongue Laboratories, Inc. Auditor Raises 'Going Concern' Doubt
BLONDER TONGUE LABORATORIES INC : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Blonder Tongue Announces Demise of Eric Skolnik, Senior Vice President
Blonder Tongue Announces Demise of Eric Skolnik, Chief Financial Officer; Appoints Michael Censoplano as Interim CFO
BLONDER TONGUE LABORATORIES INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Blonder Tongue Laboratories, Inc. Announces the Retirement of Stephen K. Necessary from the Board
BLONDER TONGUE LABORATORIES INC : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Blonder Tongue Laboratories, Inc. Announces President Changes
Blonder Tongue Laboratories, Inc. Announces Chief Executive Officer Changes
BLONDER TONGUE LABORATORIES INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
BLONDER TONGUE LABORATORIES INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Tranche Update on Blonder Tongue Laboratories, Inc.'s Equity Buyback Plan announced on July 24, 2002.
Tranche Update on Blonder Tongue Laboratories, Inc.'s Equity Buyback Plan announced on February 13, 2007.
Blonder Tongue Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Earnings Flash (BDRL) BLONDER TONGUE LABORATORIES Posts Q3 Revenue $5.3M
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BDRL
  4. Noticias Blonder Tongue Laboratories, Inc.
  5. Otros idiomas